Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be represented at three upcoming conferences: the BIO CEO & Investor Conference, the 2024 NeauxCancer Oncology Conference and H.C. Wainwright’s first Artificial Intelligence Based Drug Discovery & Development virtual conference. According to the announcement, POAI CEO Raymond F. Vennare will be presenting at all three events and will also be available for one-on-one meetings. Held in New York City, the BIO CEO & Investor Conference is slated for Feb. 26–27, 2024; Vennare’s presentation on Predictive Oncology will begin at 9 a.m. EST on Feb. 27. The 2024 NeauxCancer Oncology Conference will convene in New Orleans on Feb. 29–March 2, 2024. Vennare will be participating in both a company presentation and a panel discussion; the presentation is scheduled for 2:30 p.m. EST on March 1, and the Precision Medicine panel discussion will be held on March 2 at 12 p.m. ETS. The one-day H.C. Wainwright Artificial Intelligence Based Drug Discovery & Development Virtual Conference will feature a fireside chat by Vennare, which is scheduled for March 7, 2024, at 2 p.m. EST.
To view the full press release, visit https://ibn.fm/hHdfA
About Predictive Oncology Inc.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned Clinical Laboratory Improvement Amendments (“CLIA”) lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
